Merck (MRK) Non-Current Deferred Tax Liability (2009 - 2026)

Merck (MRK) has 18 years of Non-Current Deferred Tax Liability data on file, last reported at $1.5 billion in Q1 2026.

• Non-Current Deferred Tax Liability for Q1 2026 came in at $1.5 billion, up 6.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 6.03% YoY), and the FY2025 annual result was $1.4 billion, down 52.91% from the prior year.
• Non-Current Deferred Tax Liability improved to $1.5 billion in Q1 2026 per MRK's latest filing, from $1.4 billion in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $3.1 billion in Q1 2022 and troughed at $864.0 million in Q3 2024.
• A 5-year average of $1.7 billion and a median of $1.4 billion in 2025 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability soared 155.07% in 2022, then slumped 66.51% in 2023.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $1.8 billion in 2022, then jumped by 64.79% to $3.0 billion in 2023, then increased by 3.31% to $3.1 billion in 2024, then plunged by 52.91% to $1.4 billion in 2025, then rose by 3.82% to $1.5 billion in 2026.
• Business Quant data shows MRK's Non-Current Deferred Tax Liability at $1.5 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.